Related Experiment Video
Updated: Mar 22, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.6K
Patient Adherence to Biologic Agents in Psoriasis
1Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Dermatology (Basel, Switzerland)
|April 20, 2016
Summary
Patient adherence to biologic therapies for psoriasis is very high, with over 93% showing good medication possession. This high adherence correlates with positive patient attitudes towards their treatment for psoriasis vulgaris.
Area of Science:
- Dermatology
- Pharmacology
- Health Services Research
Background:
- Low adherence to psoriasis therapies negatively impacts treatment outcomes and increases healthcare costs.
- Patient adherence to widely used biologic agents for psoriasis remains under-investigated.
Purpose of the Study:
- To measure adherence to biologic drugs in psoriasis vulgaris patients using the medication possession ratio (MPR).
- To assess patient attitudes and beliefs regarding biologic treatments for psoriasis.
Main Methods:
- A single-center study involving 247 patients with psoriasis vulgaris treated with adalimumab, etanercept, or ustekinumab.
- Monthly MPR calculation based on hospital dispensing records.
- Patient attitudes assessed using the Medication Adherence Rating Scale (MARS).
Main Results:
- Over 93.5% of patients demonstrated an MPR ≥0.8, indicating very good adherence.
- Adherence (MPR) was not influenced by patient demographics, disease severity (PASI, DLQI), or concomitant treatments.
- Medication Adherence Rating Scale (MARS) revealed satisfactory understanding and positive attitudes towards biologic therapy.
Conclusions:
- Adherence to biologic therapies in psoriasis patients is notably high.
- High adherence is consistent with patients' positive attitudes and understanding of their psoriasis treatment.
More Related Videos
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
348
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
348
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
725
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
725
01:29Inflammatory Bowel Disease IV: Pharmacological Management
912
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
912
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
591
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
591
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
254
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
254